Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bertino, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertino, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:10-11, 2002
© 2002 European Society for Medical Oncology

Editorial

Modulation of 5-fluorouracil/leucovorin by trimetrexate—did it work?

J. R. Bertino

Memorial Sloan-Kettering Cancer Center, New York, NY, USA

In this issue of Annals of Oncology two independent randomized studies comparing weekly 5-fluorouracil (5-FU)/leucovorin (LV) with 5-FU/LV plus trimetrexate are reported [1, 2]. In addition, an integrated analysis of both studies to look at survival differences is presented [3]. The rationale for undertaking these randomized studies was strong: the addition of trimetrexate but not methotrexate to the 5-FU/LV combination was synergistic in the laboratory [4], and phase I and phase II studies were encouraging [5–7].

The need to . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?